| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/24/2001 | US6265560 Nucleotide sequences coding enzymatic polypeptide associated with signal transducton; for diagnosis, prevention, and treatment of inflammation, arthritis and physiological defects |
| 07/24/2001 | US6265556 Nucleotide sequences coding mammalian polypeptide associated with immune response and cell propagation; for the detection of modulators of apoptosis |
| 07/24/2001 | US6265543 Polypeptide for the treatment of eye disorders, tumors, cancer, psoriasis, trauma, psychological, burns and ulcers |
| 07/24/2001 | US6265450 Administering astexanthin |
| 07/24/2001 | US6265441 Nitric oxide synthase inhibitor |
| 07/24/2001 | US6265436 Substituted 5-biphenyl-3,4-dihydroxy-2(5H)-furanones and method of use therefor |
| 07/24/2001 | US6265434 Antiinflammatory agents |
| 07/24/2001 | US6265433 LTA4 hydrolase inhibitors |
| 07/24/2001 | US6265429 Administering phosphodiesrterase inhibitor |
| 07/24/2001 | US6265426 Triazole derivatives |
| 07/24/2001 | US6265425 Side effect reduction; retinoic acid metabolism blocking agent |
| 07/24/2001 | US6265419 Irritable bowel disorder |
| 07/24/2001 | US6265414 Treating sleep disorders using desloratadine |
| 07/24/2001 | US6265411 Oxindole derivatives |
| 07/24/2001 | US6265410 Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| 07/24/2001 | US6265403 Angiogenesis inhibitors |
| 07/24/2001 | US6265399 Alkylation; cyclization |
| 07/24/2001 | US6265397 Amidino derivatives and their use as thrombin inhibitors |
| 07/24/2001 | US6265390 Methods for expressing nucleic acid sequences using nucleic acid constructs comprising hypoxia response elements |
| 07/24/2001 | US6265386 In a patient undergoing treatment with an aminoglycoside antibiotic |
| 07/24/2001 | US6265377 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 07/24/2001 | US6265215 Isolated peptides which complex with HLA-Cw16 and uses thereof |
| 07/24/2001 | US6265195 Nucleic acid of defined nucleotide sequence which codes for a deoxyribonuclease; for production of enough enzyme for clinical use; diagnosis; treatment of cystic fibrosis, lupus, chronic bronchitis, pneumonia, emphysema, and asthma |
| 07/24/2001 | US6264984 Effervescent histamine H2 antagonist composition |
| 07/24/2001 | US6264966 Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
| 07/24/2001 | US6264948 Methods and compositions for inhibiting tumor cell growth |
| 07/24/2001 | US6264680 Apparatuses and processes for whole-body hyperthermia |
| 07/24/2001 | CA2331847A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 07/24/2001 | CA2230303C Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin |
| 07/24/2001 | CA2221753C Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 07/24/2001 | CA2218503C Arylsulfonyl hydroxamic acid derivatives |
| 07/24/2001 | CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients |
| 07/24/2001 | CA2191844C Acylated enol derivatives as prodrugs of elastase inhibitors |
| 07/24/2001 | CA2177774C Novel piperazine, piperidine and 1,2,5,6-tetrahydropyridine compounds; process_for preparing the same and pharmaceutical compositions containing them |
| 07/24/2001 | CA2174033C Novel pyridine compounds; process for preparing the same and pharmaceutical compositions containing them |
| 07/24/2001 | CA2030162C Benzothiazepines |
| 07/24/2001 | CA2024629C Xenopus laevis bone morphogenic protein, dna encoding same and use thereof |
| 07/24/2001 | CA2019369C Sulfur-containing fused pyrimidine derivatives, their production and use |
| 07/19/2001 | WO2001051642A2 Dna modification proteins |
| 07/19/2001 | WO2001051641A1 Irak-4: compositions and methods of use |
| 07/19/2001 | WO2001051638A2 Drug metabolizing enzymes |
| 07/19/2001 | WO2001051619A2 Genetically modified fibroblast cell |
| 07/19/2001 | WO2001051615A1 Method for increasing survival rate of cells in animal cell culture under hypoxia condition |
| 07/19/2001 | WO2001051614A1 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition |
| 07/19/2001 | WO2001051613A1 Method for inhibiting apoptosis under ischemic condition |
| 07/19/2001 | WO2001051608A2 Hybrid cells obtainable from antigen presenting cells |
| 07/19/2001 | WO2001051523A2 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | WO2001051520A2 Nogo receptor-mediated blockade of axonal growth |
| 07/19/2001 | WO2001051519A2 Potassium channel mutants of the saccharomyces cerevisiae yeast and the use thereof for the screening of eukaryotic potassium channels |
| 07/19/2001 | WO2001051512A2 Human and parasite orphan receptor proteins |
| 07/19/2001 | WO2001051493A1 Benzosulfones with calcium antagonist activity |
| 07/19/2001 | WO2001051492A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 07/19/2001 | WO2001051491A1 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 07/19/2001 | WO2001051480A1 Agents correcting gene expression regulatory error |
| 07/19/2001 | WO2001051474A2 Polypharmacophoric agents |
| 07/19/2001 | WO2001051473A1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 07/19/2001 | WO2001051470A1 Phenanthridine-n-oxides |
| 07/19/2001 | WO2001051467A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | WO2001051466A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | WO2001051463A1 Glyburide composition |
| 07/19/2001 | WO2001051462A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES |
| 07/19/2001 | WO2001051454A1 Compounds and compositions for delivering active agents |
| 07/19/2001 | WO2001051196A1 Templating of solid particles by polymer multilayers |
| 07/19/2001 | WO2001051079A1 Antigen-specific ige antibody production inhibitors |
| 07/19/2001 | WO2001051071A2 Transepithelial delivery of glp-1 derivatives |
| 07/19/2001 | WO2001051064A1 Ph-regulators against oral stereotypies in equines |
| 07/19/2001 | WO2001051058A1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
| 07/19/2001 | WO2001051055A2 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | WO2001051053A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 07/19/2001 | WO2001051048A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 07/19/2001 | WO2001051047A1 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 07/19/2001 | WO2001051032A2 Micronized freeze-dried particles |
| 07/19/2001 | WO2001051003A2 Use of lipid conjugates in the treatment of disease |
| 07/19/2001 | WO2001050848A2 Clonal propagation of primate offspring by embryo splitting |
| 07/19/2001 | WO2001014414A3 Human abc2 transporter and uses thereof |
| 07/19/2001 | WO2001012632A3 Phenanthroline-7-one derivatives and their therapeutic uses |
| 07/19/2001 | WO2001009076A3 Retinoids for the treatment of emphysema |
| 07/19/2001 | WO2001006261A3 Screening for therapeutic agents being scap antagonists |
| 07/19/2001 | WO2001005969A3 Electron transfer proteins |
| 07/19/2001 | WO2001005820A3 Method for down-regulating gdf-8 activity |
| 07/19/2001 | WO2001005758A3 Indoles and indazoles for the treatment of migraine |
| 07/19/2001 | WO2001005418A3 Tissue regenerating agent |
| 07/19/2001 | WO2001005392A3 Method for treating chronic pain using mek inhibitors |
| 07/19/2001 | WO2001005383A3 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 07/19/2001 | WO2001005353A3 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 07/19/2001 | WO2001004297A3 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 07/19/2001 | WO2001004118A3 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 07/19/2001 | WO2001001998A3 Treatment of endometriosis with antileukoprotease |
| 07/19/2001 | WO2000076984A8 Novel compounds, their use and preparation |
| 07/19/2001 | WO2000073324A3 Modulation of gene expression in gastrointestinal inflammation |
| 07/19/2001 | WO2000071104A3 Use of bisphosphonic acids for treating angiogenesis |
| 07/19/2001 | WO2000069891A3 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins |
| 07/19/2001 | WO2000064485A9 Specifically targeted catalytic antagonists and uses thereof |
| 07/19/2001 | WO2000055321B1 Vertebrate protein slit, dna sequence encoding it and uses thereof |
| 07/19/2001 | US20010008947 Administering derivative of 2-amino-4-phenyl-4-oxo-butyric acid which acts as kynureninase/kynurenine-3-hydroxylase enzyme inhibitor; neurodegenerative diseases |
| 07/19/2001 | US20010008936 Oligonucleotides having chiral phosphorus linkages |
| 07/19/2001 | US20010008933 Novel disulfides and thiol compounds |
| 07/19/2001 | US20010008905 Administering a compound such as hydroxyurea to deplete the intracellular pool of deoxyribonucleoside phosphate |
| 07/19/2001 | US20010008903 Dioxinoindole and thienobenzodioxin compounds which are ht3 receptor antagonists and are used to treat central nervous system disorders |
| 07/19/2001 | US20010008895 Reacting 17 beta-(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent |